Insulet Corporation reported robust financial results for the fourth quarter of 2025, with adjusted earnings per share of $1.55, reflecting a 34.8% year-over-year increase. Fourth-quarter revenues hit $783.8 million, surpassing market expectations and showcasing a 31.2% growth compared to the prior year. The company recorded a strong demand for its Omnipod insulin management systems and expanded its U.S. prescriber base, contributing to a full-year revenue of $2.71 billion, a 30.7% increase from 2024. Looking ahead, Insulet projects continued growth in 2026, expecting a revenue increase of 20-22%.
“Insulet · is up · value · +8%”
“Insulet Corporation · reported · fourth-quarter 2025 adjusted earnings per share (EPS) · $1.55”
“Insulet Corporation · reported · fourth-quarter 2025 adjusted earnings per share (EPS) · 34.8% increase from the year-ago period”
“Insulet Corporation · GAAP EPS came in at · fourth-quarter 2025 · $1.44”
“Insulet Corporation · reported · full-year 2025 EPS · $4.97”
“Insulet Corporation · reported · full-year 2025 EPS increase · 53.4%”
“Insulet Corporation · reported · full-year 2025 revenues · $2.71 billion”
“Insulet · expects · 2026 revenue growth · between 20% and 22% from 2025”
“Insulet · is up · percentage · +8%”
“Insulet · is up · 8% · +8%”
“Insulet Corporation · achieved · consecutive year of 20%+ revenue growth · 10th”
“Insulet Corporation · expanded the U.S. prescriber base by · health care professionals · 28% to 30,000”